Laparoscopy Devices Market: USD 13.37 Billion by 2031, Growth Fueled by Robotic Surgery and Advanced Visualization, Says Mordor Intelligence

Mordor Intelligence estimates the global laparoscopy devices market at USD 9.29B in 2026, rising to USD 13.37B by 2031 (7.55% CAGR), supported by a shift toward minimally invasive procedures and faster recovery benefits. Growth is further driven by adoption of advanced visualization (4K/3D, AR, and AI-enabled imaging) and increasing penetration of robotic-assisted laparoscopy systems, with North America the largest region and Asia-Pacific the fastest-growing. Manufacturers are also investing in next-gen energy/access devices and connected/AI-enabled platforms, alongside reusable designs to address sustainability considerations.

Analysis

The investable read-through is less about topline growth and more about mix: procedure growth only accrues to vendors with durable installed bases, high-margin disposables, and meaningful service/software pull-through. That structurally favors broad surgical platforms like JNJ and Olympus-style visualization franchises over commoditized access/handheld categories, while MDT remains a show-me story until it proves its robotic and adjacent laparoscopy stack can win utilization, not just placements. ASCs are a subtle negative for pricing power: they accelerate procedure volume, but they also intensify procurement discipline and shorten the payback hurdle on capital purchases.

Near term, this is not a days-trade catalyst; it matters into the next 1-3 earnings cycles when management commentary can confirm whether elective procedure momentum is translating into order growth and consumables attach rates. The key falsifier is any sign that hospital capex stays weak or that robotics adoption cannibalizes traditional laparoscopic systems faster than the category expands, in which case the benefit accrues more to ISRG-like ecosystems than to legacy tool vendors. Another risk is that sustainability-driven demand for reusable/lower-plastic products compresses unit growth for disposable-heavy portfolios even if procedure counts rise.

Consensus is likely over-simplifying this as a straightforward TAM expansion. The more important question is who captures the margin: high-spec visualization, energy, and recurring accessories should outperform lower-end instruments, and that dispersion can widen if APAC growth is more price-competitive than North America. On that basis, the move looks underappreciated for the highest-quality surgical franchises, but probably overdone if investors are extrapolating broad-based beta across the entire medtech basket.

Key Decisions for Investors

• Long JNJ / short MDT as a 3-6 month relative-value pair: JNJ has better surgical consumables resilience and less execution risk; MDT needs proof that its minimally invasive portfolio is translating into utilization, not just narrative.
• Accumulate OLYMY on weakness over the next 1-2 quarters as a quality exposure to visualization and endoscopy pull-through; keep sizing modest due to ADR liquidity and the risk that pricing pressure offsets volume growth.
• Avoid chasing pure-play laparoscopy suppliers on the press-release alone; wait for earnings confirmation of procedure growth, ASP stability, and capital order backlog before adding BSX or other surgical-tool exposures.
• Set an alert on MDT and JNJ next guidance cycle: if management cites elective-procedure strength but flat or down capital equipment orders, fade the breadth trade and rotate toward consumables-heavy names.